Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US62855J1043
Ticker MYGN
Company MYRIAD GENETICS
Currency $
Price
Aware Investor Index (AII) 0.1970
Recommendation HOLD
P/E 19.25
ROE 11.63 %
Capitalization 2,159,280,000 $
Dividend Yield 0.00 %
P/S 2.79
AII Position 408
P/E Position 233
ROE Position 312
Capitalization Position 640
Dividend Yield Position 595
Sales 772,600,000 $
10-Year Average Earnings 112,174,300 $
Shares Outstanding 72,000,000
Equity 964,900,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
MYRIAD GENETICS Investor Relations Web Site http://investor.myriad.com







Sales:

YEAR MONTH AMOUNT
2018 6 772,600,000.00 $
2017 6 769,900,000.00 $
2016 6 740,500,000.00 $
2015 6 722,500,000.00 $
2014 6 778,216,000.00 $
2013 6 613,165,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 6 131,100,000.00 $
2017 6 20,500,000.00 $
2016 6 117,200,000.00 $
2015 6 79,800,000.00 $
2014 6 176,225,000.00 $
2013 6 147,139,000.00 $
2012 6 112,151,000.00 $
2011 6 100,710,000.00 $
2010 6 152,303,000.00 $
2009 6 84,615,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 6 964,900,000.00 $
2017 6 768,000,000.00 $
2016 6 739,600,000.00 $
2015 6 661,700,000.00 $
2014 6 718,998,000.00 $
2013 6 728,594,000.00 $
2012 6 635,660,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 6 72,000,000
2017 6 68,800,000
2016 6 72,400,000
2015 6 74,500,000
2014 6 78,182,000
2013 6 83,327,000
2012 6 86,465,000

 












Bloomberg News for MYRIAD GENETICS:



Google News for MYRIAD GENETICS:

Fairfield Current - 47 minutes ago
Myriad Genetics (MYGN) Announces Earnings Results, Beats ...
Myriad Genetics (NASDAQ:MYGN) posted its quarterly earnings results on Tuesday, November 6th. The company reported $0.43 earnings per ...
Stock Digest (press release)
Myriad Genetics updates revenue guidance
Myriad Genetics (NASDAQ:MYGN) is on watch after setting guidance below the expectations of analysts due to transitory issues identified with ...
PressOracle
Myriad Genetics (MYGN) Beats on Earnings in Q1, Revenues Lag
Myriad Genetics exited first-quarter fiscal 2019 with cash, cash equivalents and marketable securities of $167.5 million compared with $180.6 ...
The RNS Daily
Myriad Genetics down 12% on FDA nod for 23andme test for drug ...
Myriad Genetics (MYGN -12.4%) is down on more than double normal volume in apparent response to the FDA's approval of 23andme's ...
Seeking Alpha - 7 Nov 2018
Myriad Genetics (MYGN) Earnings Expected to Grow: What to Know ...
Wall Street expects a year-over-year increase in earnings on higher revenues when Myriad Genetics (MYGN) reports results for the quarter ...
GlobeNewswire (press release)
Myriad Genetics to Present at the Stephens New York Investment ...
SALT LAKE CITY, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and ...
Nasdaq
Myriad Genetics, Inc. (NasdaqGS:MYGN) Adjusted Slope Reading ...
Shares of Myriad Genetics, Inc. (NasdaqGS:MYGN) are showing an adjusted slope average of the past 125 and 250 days of 11.42856.
Motley Fool
Checking on Chart Signals for Myriad Genetics Inc (MYGN)
Investors may be setting their sights on shares of Myriad Genetics Inc (MYGN). After a recent scan, we have seen that the 50-day MA vs Price ...
Zacks.com - 6 days ago
Myriad Genetics (MYGN) Announces FDA Approval of ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food ...
FDA Headlines
Myriad to Present New Data from Its Industry-Leading Portfolio of ...
12, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that 10 ...


Back